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Abstract Stimulation of the PI3K/Akt/mTOR pathway,
which controls cell proliferation and growth, is often
observed in cancer cell. Inhibiting both PI3K and mTOR in
this pathway can switch off Akt activation and hence, plays
a powerful role for modulating this pathway. PKI-587, a
drug containing the structure of morpholino-triazines,
shows a dual and nano-molar inhibition activity and is
currently in clinical trial. To provide an insight into the
mechanism of this dual inhibition, pharmacophore and
QSAR models were developed in this work using com-
pounds based on the morpholino-triazines scaffold, fol-
lowed by a docking study. Pharmacophore model
suggested the mechanism of the inhibition of PI3Ka and
mTOR by the compounds were mostly the same, which
was supported by the docking study showing similar
docking modes. The analysis also suggested the importance
of the flat plane shape of the ligands, the space surrounding
the ligands in the binding pocket, and the slight difference
in the shape of the binding sites between PI3Ka and
mTOR.




mTOR Mammalian target of rapamycin
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase
QSAR Quantitative structure–activity relationship
MAC Most active compound
LAC Least active compound
Introduction
The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/
serine/threonine-specific protein kinase (Akt)/mammalian
target of rapamycin (mTOR) pathway regulates cell prolif-
eration and cell growth and is often stimulated in cancer,
which makes it an important target pathway for cancer
therapies [1, 2]. Activation of Akt is responsible for cell
proliferations and cell translation. Akt is activated by PI3K
indirectly, which results in the phosphorylation at Thr 308,
while mTORC2 (mTOR complex 2) can activate Akt by
phosphorylating Ser 473. mTORC1 (mTOR complex1) is
downstream of Akt and can produce a negative feedback on
the PI3K signaling activation. To fully activate Akt, phos-
phorylation of both Thr 308 and Ser 473 is necessary.
Interestingly, although the sequence identity of the catalytic
sites was low (Supplementary Material), PI3K and mTOR
share a high structure similarity at their catalytic sites.
Therefore, a drug with dual inhibition activity for both PI3K
and mTOR may be developed to shut down Akt activation.
Dual inhibitors of PI3K/mTOR with various scaffolds
have been developed. Some of these inhibitors are in
clinical trials including BGT226 [3], NVP-BEZ235 [4],
XL765 [5] and PKI-587 [6, 7]. PKI-587 has been designed
Electronic supplementary material The online version of this
article (doi:10.1007/s10822-016-9905-4) contains supplementary
material, which is available to authorized users.
& Yanli Wang
ywang@ncbi.nlm.nih.gov
1 National Center for Biotechnology Information, National
Library of Medicine, National Institutes of Health, Bethesda,
MD 20894, USA
123
J Comput Aided Mol Des (2016) 30:323–330
DOI 10.1007/s10822-016-9905-4
based on the scaffold of morpholino-triazines, shows a
sub-nano molar potency, and has attracted many research
interests with recent studies demonstrating multiple clin-
ical advantages. Recently it has been reported that PKI-
587 can help cetuximaub (an inhibitor of epidermal
growth factor receptor) to increase its sensitivity in
resistant cell lines [8]. Also, PKI-587 inhibits the propa-
gation of the cancer stem cell in liver with and without
sorafenib [9] although the mechanism of action for this
bioactivity is unclear. Clinical information about PKI-587
can be found in the clinical trials database (ClinicalTrials.
gov) with multiple data entries: NCT02438761, phase II,
for assessment of its ‘‘efficacy for patients with myeloid
neoplasm secondary to chemo-radiotherapy (t-AML/
MDS) and refractory AML’’; and NCT01920061, phase I,
for ‘‘assessment of its safety and tolerability in combi-
nation with other anti-tumor agents (Docetaxel, Cisplatin,
Dacomitinib)’’ [10–12].
Pharmacophore modeling, 3D-QSAR (quantitative
structure activity relationship) modeling, and docking are
widely used in computer-aided drug design approaches.
Pharmacophore modeling identifies the common structural
and physicochemical features of a set of compounds that
bind to the target molecules. QSAR modeling constructs
mathematical formula between molecular structure features
and its biological activities so that it can be used for
screening chemical database for new lead compounds [13].
Docking studies can predict the binding mode and provide
insight into the interaction between the ligand and the
target.
The study of the structure and bioactivity relationships
using the scaffold that led to the development of PKI-587
may provide molecular insights to the inhibition activity of
this dual inhibitor and facilitate further development of
additional dual PI3K/mTOR inhibitors and drugs. The aims
of this study were to investigate the molecular basis of the
inhibition against PI3K/mTOR and to identify the structure
features of the compounds with morpholino-triazine scaf-
fold that primarily contribute to the inhibition of PI3K/
mTOR. We have conducted pharmacophore modeling,
atom-based QSAR, and molecular docking studies, which
consistently showed that the mechanisms for inhibiting
PI3K and mTOR were mostly the same. The docking study
showed that the compounds formed hydrogen bonds (HBs)
with the corresponding residues that form HBs with ATPs
in the X-ray crystallography structures of PI3Kc. In addi-
tion, the outmost active compounds formed a HB with the
amine moiety on the other end of the molecule, which
showed as the main difference between the most active and
the least active compound in the docking study. Similarity
of the binding modes of PKI-587 to PI3K and mTOR
suggested it is important to the dual inhibitor design.
Docked complex structures for the most active compounds
were compared to the selective/multi-target inhibitors’
complex structures with the enzymes.
Methods
Compounds and their activities
Activities (IC50) of bis (morpholino-1,3,5-triazine)
derivatives for PI3Ka and mTOR were retrieved from
PubChem Assay [14] (PI3Ka—AID 460017, AID 609982,
and mTOR—AID 460019, AID 610010) based on two
articles [6, 7] and a total 40 compounds are shown with
PubChem compound ID (CID) [15] in Table S1 in Sup-
plementary Material. 2D-molecular structures for these
compounds were downloaded from PubChem as 2D-SDF
files. As mutations and overexpression of PI3KCA, the
gene of PI3Ka, are observed in many cancers, PI3Ka was
chosen for the modeling among PI3K isoforms.
Pharmacophore and QSAR modeling
The Phase program on Maestro (Schro¨dinger, LLC, New
York, NY, 2013) was used for pharmacophore modeling
and 3D-QSAR modeling. IC50 values were converted to
pIC50. 2D-structures were converted to 3D structures and
energy minimization was performed. The conformers were
generated by ConfGen [16] equipped in Phase with the
default parameters: the number of conformers per rotat-
able bond was set to 100, the maximum number of con-
formers per structure was set to 1000 with distance-
dependent dielectric solvation model, and energy mini-
mization was performed using the OPLS2005 force field.
Pharmacophore models were built with the five most active
compounds (MAC) for each enzyme. The least active
compounds were used to deny hypotheses that do not
distinguish between most active and least active com-
pounds. These compounds were shown in Table S3 in
Supplementary Material. The number of pharmacophore
sites and minimum matches was set to five. The common
pharmacophore search was carried out by binary decision
tree using the distances between two sites. For scoring
parameters, the weight of selectivity score was set to 1.0
and the other parameters were kept as default. High
selectivity scores indicate the hypothesis is unique to the
actives.
The compounds in the training set aligned to the top
pharmacophore hypotheses were used for building atom-
based QSAR model by partial least square (PLS) regression
[17] with the maximum factor set to 3. The PLS method
builds a set of models with different number of factors.
Larger numbers of factors lead to better description of the
training set at the risk of overfitting. In this study, we used
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the PLS method to build three sets of models (i.e. maxi-
mum factor = 3), and we chose the most accurate but not
over-fitted model. In atom-based QSAR, atoms were
classified into six types: hydrogen-bond donor (D),
hydrophobic or nonpolar (H), negative ionic (N), positive
ionic (P), electron-withdrawing (W), and others (X). To
represent an atom, a spherical model with van der Waals
radius of its atom types was used. A rectangular grid was
set to cover the space of the aligned training set compounds
and divided by 1 A˚3 cubes. The independent variables of
PLS regression take values of 0 or 1 depending on the
cubes and its occupied atom types. The activity of the
compounds was the dependent variable. Training set and
test set for the QSAR models were selected so that the
activities of the compounds were uniformly distributed for
both sets with the ratio of the training set size over the test
set size as 1:1. Two compounds (CID56683918 and
56683919) were removed for QSAR building because they
were not aligned well to the pharmacophore hypothesis.
For QSAR building of mTOR, one compound
(CID56683917) was removed as an outlier.
Docking
We docked PKI-587, CID 53379513 (MAC, the most
active compound), and CID 46228569 (LAC, the least
active compound) to PI3Ka. We also docked PKI-587, CID
44514208(MAC), and CID 56683919(LAC) to mTOR.
Induced Fit Docking (IFD) was carried out, which used
Glide version 6.1 and Prime version 3.4 (Schro¨dinger,
LLC, New York, NY, 2013) [18, 19] on Maestro version
9.6. The IFD protocol was employed and the default set-
tings were chosen except the trim side chain option was
selected.
The protein structures of PI3Ka and mTOR were taken
from the Protein Data Bank (PDB) with PDB ID code 4L23
and 4JT6 [20], respectively. Both protein structure com-
plexes contain the same ligand in the PDB files. The Pro-
tein Preparation module on Maestro with default settings
was used to prepare the protein structures.
2D-SDF files for small molecule compounds down-
loaded from PubChem were prepared by LigPrep, version
2.8 (Schro¨dinger, LLC, New York, NY, 2013) with default
settings with OPLS2005 force field. Box size was set to
‘‘Dock ligands with length B50 A˚’’ for MAC and to
‘‘Auto’’ for LAC since MAC were larger than LAC and the
ligand in the original PDB files. The Induced Fit program
reproduced the complex in 4JT6 with ligand-RMSD
0.85 ± 0.43 A˚ for the top 5 ranked structures from docked
complex outputs. 98 % of the residues located within 4 A˚
from the ligand in the original complex structure remained
close (within 4 A˚) to the ligand in the top 5 ranked struc-
tures from the docked complexes. MAC for PI3Ka and that
for mTOR were larger than the ligand in 4L23. Hence, for
testing docking with a ligand with comparable size, we
used 3IBE, a structure complex of PI3Kc that has a larger
ligand. Similarly to the docking result for 4JT6, the
docking result for 3IBE through induced fit docking
reproduced the structure complex with an average ligand-
RMSD 1.50 ± 0.98 A˚ for the top 5 ranked struc-
tures. 95 % of the residues within 4 A˚ to the ligand in the
original complexes remained close (within 4 A˚) to the
ligand in the top 5 ranked docked complexes.
Induced fit docking was carried out as flexible confor-
mations can be generated depending on the various size of
the compounds. It allows protein side chain and backbone
movements. This is necessary since the compound sizes in
this study were larger than that of the ligands in the PDB
files above. In addition, Yang et al. [21] and Knight et al.
[22] reported that the X-ray crystal structures complexes
with the inhibitors showed conformational changes upon
binding of the inhibitors to the enzymes. In the IFD pro-
tocol, Glide docking with softened potential and side chain
removal according to the B-factor was first carried out.
Then, the results were clustered based on the scores and the
descriptors. Next, the side chains in which residues are
within a distance of 5 A˚ were predicted and the residues
and the ligands in the complex pose were minimized by




Pharmacophore models were the same for inhibitors for
both PI3Ka and mTOR enzymes. In Fig. 1, MAC for
PI3Ka was mapped with the pharmacophores of the highest
scores. Pharmacophore models for PI3Ka and mTOR were
AADPR, where A, D, P or R represents a hydrogen bond
acceptor, a hydrogen bond donor, positive feature, or an
aromatic ring, respectively. For both models, the two As
were on the triazine nitrogens, and D was on the urea
nitrogen. P was on the amine on the end of the molecules
and R was on aromatic ring next to triazine.
QSAR
Table S3 shows the observed and predicted activities. We
randomly split the training and test set three times and
calculated the average of the coefficients with uniform
distribution of the activities of the compounds. The average
and standard deviation of correlation coefficients of atom-
based 3D-QSAR models for the training set (R2) and test
set (Q2) for PI3Ka and mTOR were in R2 = 0.74 ± 0.05,
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Q2 = 0.65 ± 0.08 and R2 = 0.69 ± 0.04, Q2 = 0.56 ±
0.09, respectively. Q2 for both models were over 0.5.
The combined hydrophobic/non-polar and electron-
withdrawing effects through the QSAR modeling for
PI3Ka and mTOR are shown on the aligned structures for
the five most active compounds in Figure S1 in Supple-
mentary Material. MACs for both enzymes had combined
hydrophobic/non-polar and electron-withdrawing effects at
both ends of the compound structures including a mor-
pholine and an amine moiety contributing to the inhibition
activity.
Binding modes
X-ray structures of PI3Ka and mTOR were reported only
recently [21, 23]. The PI3Kc- complex structure had been
used previously to build homology models for the docking
study of PI3Ka [6, 7]. We now conducted docking to study
the ligand–protein interaction using the available PI3Ka
and mTOR x-ray structures. Ligand interaction diagrams of
the modeled structure complex are shown in Figure S2 and
S3 in Supplementary Material for MACs and LACs with
PI3Ka and mTOR respectively. The cut-off distance for
interaction selection was set as 4 A˚.
Based on the binding mode of MAC (CID 53379513)
docked to PI3Ka (shown in Figure S2 (A) in Supplemen-
tary Material), the oxygen atom of the morpholine moiety
formed a hydrogen bond (HB) with the backbone of Val
851. As shown in Figure S2 (A), the CH2 groups of the
morpholine moiety are hydrophobic and surrounded by the
hydrophobic residues, which agrees with the positive
contributions of the combined hydrophobic/non-polar and
electron-withdrawing effects on the morpholine group to
the inhibition activity suggested by the QSAR modeling
(shown in Figure S1). Besides, Figure S6 (B) shows that
the morpholine and R1 group bind to non-polar region. Val
851 in PI3Ka corresponds to Val 882 in PI3Kc which
forms a HB with adenosine 50-triphosphate (ATP) in the
ATP-bound PI3Kc crystal structure [24]. In addition, the
urea moiety formed HBs with Lys 802 and Asp 810, the
amide moiety formed a HB with His 936, and the amine
moiety formed a HB with Asp 805. The hydrogen atom of
this urea group was captured in the pharmacophore model
as a hydrogen bond donor (Fig. 1). For Lys 802 in PI3Ka,
its corresponding residue Lys 833 in PI3Kc forms a HB
with ATP [25]. Therefore, these HBs formed with Val 851
and Lys 802 are crucial for the ligand binding as an ATP-
competitive drug. The other residues of PI3Ka, which
correspond to the HB-forming residues in the ATP-bound
PI3Kc structure, are Ser 774, Glu 849, Gln 920, and Asp
933. Among them, Ser 774, Glu 849, and Asp 933 were
observed within 4 A˚ from the ligand in the docked com-
plex structure. Based on the previously reported binding
mode of CID 53379513 docked to the conformation of
PI3Ka derived through homology modeling, the morpho-
line moiety formed a HB with Val 851 and urea formed
HBs with Lys 802 and Asp 810 [6]. When docking LAC
(CID 46228569) to PI3Ka (shown in Figure S2 (B) in
Supplementary Material), the binding mode was similar to
that of the MAC. The difference was that Ser 774 was not
observed within a 4 A˚ distance from the ligand comparing
to the docked mode for MAC. In Figure S4 (A) in Sup-
plementary Material, the binding mode of PKI-587 (CID
44516953) to PI3Ka showed all key HBs formed in the
binding mode of MAC but Ser 774 was not observed within
4 A˚ from the ligand similarly to the observation in the
docked mode for LAC. Molecular dynamics (MD) simu-
lation was applied to docked structures (docked poses) to
check the stability of the binding modes (Supplementary
Material). The HBs formed between Val 851 and mor-
pholine oxygen, between Lys 802 and urea oxygen, and
between Asp 810 and urea hydrogens were observed with a
high frequency during the 5 ns MD simulation, indicating
the significance of their contributions for ligand-receptor
binding and the stability of the docked modes. Estimated
binding free energy with MM-GBSA for each binding
mode was shown in Table S5 in Supplementary Material.
For PI3Ka, the calculated binding free energy for PKI-587
Fig. 1 Pharmacophore model
shown on MAC of PI3Ka. Pink:
HB acceptor; light blue: HB
donor; purple: positive feature;
orange ring: aromatic ring
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was slightly higher than MAC, but the order of the esti-
mated binding free energy correlated in general with the
order of the experimental activities of the ligands.
Figure 2 shows the overlay of the binding sites in the
docked modes for MAC and LAC to PI3Ka. Most parts of
the MAC and LAC molecules were flat except those at the
two ends. MAC is bigger in size and longer in shape
comparing to LAC. The figure shows a region in MAC that
was surrounded by the negatively charged or polar residues
and bent upwards away from the flat region, which sup-
ported the suggestion from that pharmacophore model for
positive feature at the end of this section of the molecule.
MAC made extra HBs with His 936 and Asp 805 fitting
into the region consisting of the residue Asp 806, Gln 809,
and Glu 1012. The position of the side chain of His 936 in
the docked mode of PI3Ka bound with MAC slightly
shifted towards MAC comparing to its position in the LAC
bound mode. MAC also formed a HB with the amine at the
end of the molecule to the opposite side of the morpholine
group. The tetrahydrofuran group in MAC stuck out of the
flat plane region (which consists of most fragments of the
MAC) towards Met 722, and the sidechain of Trp 780
shifted slightly closer to the group than that in the LAC
bound mode. In addition, the side chain of Met 858 flipped
toward the tetrahydrofuran group in MAC.
Knight et al. [22] suggested that the selectivity of iso-
form-selective PI3K inhibitors resulted from the fit of the
inhibitors into the pocket induced by the inhibitors between
Met 804 and Trp 812 in PI3Kc (corresponding residues,
Met 772 and Trp 780 in PI3Ka). The quinazoline moiety of
PIK-39 in the PI3Kc crystal structure complex, occupies
the pocket between Met 804 and Trp 812. It is perpen-
dicular to the plane of the other part of the PIK-39 mole-
cule. PIK-39 and other PI3K selective inhibitors tend to
have the fragment sticking out of the plane structures while
multi-target inhibitors tend to have solely flat structures. In
terms of the molecular shape, both MAC and LAC for
PI3Ka revealed mostly flat structures, which indicated that
they were dual inhibitor candidates indeed.
For selective PI3Ka inhibitor design that uses the mor-
pholino-triazine scaffold, substituting tetrahydrofuran to
the polycyclic aromatic group in the MAC structure might
induce Met 772 movement and create a pocket between
Met 772 and Trp 780 like PIK-39. Knight et al. also
reported that the potent selective inhibitors bound deeply
into the ATP binding pocket by forming two HBs with the
backbone of Val 882 and Glu 880 in PI3Kc. Adding
additional hydrogen bond donors on the morpholine moiety
of MAC might build extra HB with the backbone of Glu
849 in PI3Ka and lead the compound to insert more deeply
into the adenine pocket.
The binding mode of MAC (CID 44514208) docked to
mTOR (Figure S3 (A) in Supplementary Material) showed
HBs between morpholine and Val 2240, the urea moiety
and Asp 2195, and the amine moiety and Asp 2360. In
addition, the anime moiety formed a salt-bridge with Asp
2433. This agrees with the pharmacophore model where
positive feature is at the end to the opposite side of the
morphoine and triazine group (Fig. 1). Information of the
corresponding residues in ATP-bound PI3Kc for mTOR is
provided in the Supplementary Material. The binding mode
of LAC (CID 56683919) docked to mTOR showed a HB
between urea and Lys 2187 but did not show any HB with
Asp 2360 or salt-bridge with Asp 2433 (Figure S3 (B) in
Supplementary Material). The binding mode for the PKI-
587-mTOR model showed the same HBs formed as that in
the MAC-mTOR model in addition to the HB formed
between Lys 2187 and the oxygen of the urea. Additionally
a salt-bridge formed between the amine moiety of PKI-587
and mTOR/Asp 2360 (Supplementary Material Figure S4
(B)). As observed in the model docked to PI3Ka, the
morpholine moiety was in the hydrophobic pocket agreeing
with the combined effects from QSAR modeling, and the
urea hydrogen atom formed a HB, which was indicated in
the pharmacophore model. Furthermore, the key HBs
formed between Val 2240 and morpholine/oxygen, Lys
2187 and urea/oxygen, and Asp 2195 and urea/hydrogen
atoms were observed with a high frequency during the 5 ns
MD simulation (Supplementary Material). For mTOR, the
estimated binding free energy of MAC and PKI-587 was
both lower than that of LAC, though the estimated free
energy of MAC was higher than that of PKI-587, sug-
gesting more accurate free energy calculation may be
needed.
Figure 3 shows the overlay of the binding sites in the
models for MAC and LAC docked to mTOR. MAC and
LAC occupied almost the same space in the docked model,
and both structures were adopting mostly a flat plane
conformation as observed in the docked modes of the MAC
Fig. 2 Overlay of the docked structure of MAC and LAC for PI3Ka.
Tan: MAC and PI3Ka, blue: LAC and PI3Ka
J Comput Aided Mol Des (2016) 30:323–330 327
123
and LAC in PI3K. This flatness of the molecule is partially
supported by the aromatic ring of pharmacophore in the
pharmacophore model. However, a large difference was
found between the complex structures with MAC and LAC
in the position of Trp 2429. Trp 2429 in the LAC-mTOR
complex was closer to the end of LAC while Trp 2429 in
the MAC-mTOR complex opened up the space presumably
to avoid the steric crash between the –N(CH3) group of
MAC next to the carbonyl and Trp 2429. In addition, Glu
2190 of mTOR bound with MAC flipped to the opposite
direction comparing to its orientation in the LAC-mTOR
complex, and was close to the aromatic ring next to the
urea group as if it attempts to close the space opened up by
the shift of Trp 2429. The side chain of Trp 2239 in the
MAC-mTOR complex shifted slightly towards the –
OC(CH3)2 group of triazine. For both MAC and LAC, the
end part of the molecule which is on the other side of
morpholine bent towards the region consisting of Asp 2360
and Asp2433 and stuck out of the flat plane of the ligand
molecule (in Fig. 3 going downwards).
Yang et al. [21] reported that a mTOR selective inhi-
bitor, Torin2, had stacking effect between its aromatic ring
and Trp 2239, and that Torin2 is surrounded by a pocket
consisting of Ile 2163, Pro 2169, and Leu 2185. Neither
MAC nor LAC in the docked structure showed a similar
stacking effect from the aromatic ring with Trp 2239.
However, the docking model suggested that such stacking
effect may be formed if MAC and LAC would insert
deeper into the hinge region, or if Trp 2239 would shift to
certain extent towards the ligands. This analysis suggests
that introducing a polycyclic aromatic ring group at the
position of the extended flat plane of the ligand’s structure
may be critical for improving inhibition selectivity through
stacking effects. Yang et al. also reported that another
mTOR selective inhibitor, PP242, showed conformational
change of the hydrophobic pocket upon its binding to
mTOR, which involved residue Tyr 2225, Gln 2223, and
Leu 2354. Among those residues, they suggested Leu 2354
was the key residue for the compound’s selectivity towards
mTOR over PI3Ks because the PI3Ks and mTOR differ in
sequence at that position of Leu 2354 in mTOR where
phenylalanine is found in PI3Ks. However, the docked
models for MAC-mTOR and LAC-mTOR did not show
significant conformational changes as those caused by the
binding of the selective inhibitor PP242 to mTOR, which
may help to explain why compounds including MAC and
LAC were showing dual inhibition activity rather than
selectively favoring mTOR or PI3K.
Comparing the docked modes for PKI-587 and MAC to
PI3Ka and mTOR, PKI-587 binds more similarly to
PI3Ka and mTOR, while larger differences were observed
in the models for MAC and the enzymes. In MAC-
PI3Ka, MAC formed HBs with Lys 802 and His 936 but
no salt-bridge was observed. Conversely, in MAC-mTOR,
no HB was formed between MAC and the corresponding
residues of mTOR though a salt-bridge was formed. When
looking into the docked modes of PKI-587 to PI3Ka and
mTOR, while a salt-bridge was found in PKI-587-mTOR
but not in PKI-587-PI3Ka, two binding modes otherwise
showed a similar HB pattern. This ‘‘reduced’’ difference
may help to explain the dual inhibition activity of PKI-
587 and shed a light for designing dual vs. selective
inhibitors.
Both MAC and LAC docked to PI3Ka by occupying a
larger space in the pocket compared to the binding modes
of mTOR inhibitors. In the docked structures for MAC-
PI3Ka and LAC-PI3Ka, the areas of the receptor surface
within 4 A˚ from the ligand were 1661 and 1344 A˚2
respectively while for MAC-mTOR and LAC-mTOR the
areas were 1256 and 961 A˚2. The overlay of the binding
sites in the modes for MAC and LAC docked to PI3Ka and
mTOR are shown in Figs. 2 and 3 respectively. The bound
structures of MAC and LAC aligned well with each other.
The areas of the receptor surface within 4 A˚ from PKI-587
in the modes docked to PI3Ka and mTOR were 1461 and
1100 A˚2, respectively, which fall in between the surface
area obtained from the respective MACs-receptor and
LACs-receptor docked structures. It is noteworthy that the
order of receptor surface areas in the ligand-receptor
docked structures correlated to certain extent with the order
of ligand inhibition activities. Figure S6 (A) in Supple-
mentary Material shows the superimposed binding site
surface of PI3Ka and mTOR bound with PKI-587, which
indicated that PI3Ka possessed a larger opening space in
the binding pocket where morpholine and the R1 group of
the ligand bind, which opens up toward its C-terminal
section.
Overall the docked modes of the inhibitors for both
PI3Ka and mTOR indicated that inhibitors with the mor-
pholino-triazine scaffold had mostly the same inhibition
Fig. 3 Overlay of the docked structure of MAC and LAC for mTOR.
Tan: MAC and mTOR, blue: LAC and mTOR
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mechanism. MACs mainly had flat structures except the
parts at the terminal of the compounds. They formed HBs
between the morpholine moiety and a valine in the
receptor’s hinge region, the urea moiety and an aspartic
acid of the receptor, and the amine moiety at the terminal
part of the ligand and the aspartic acid in the region of the
receptor that consists of negatively charged or polar resi-
dues. LACs docked to the enzymes by forming HBs only at
the morpholine and urea moieties. This relative shortage of
HBs in the LAC complexes seems to be the primary reason
accounting for the bioactivity difference. A larger differ-
ence between MAC-PI3Ka and MAC-mTOR lied mainly
in the shape of the binding sites. PI3Ka possessed a larger
opening of binding site. In addition, the docked confor-
mation of MAC in PI3Ka bent towards the N-terminal
section (upwards in Fig. 2) while that in mTOR bent
towards the C-terminal section (downwards in Fig. 3). This
difference might be utilized as another strategy for the
design of selective inhibitors, which is in addition to the
suggestion for introducing a polycyclic aromatic group to
gain ring stacking effects with Trp 780 for PI3Ka and Trp
2239 for mTOR depending on the direction of each tryp-
tophan in the respective enzyme target. The receptor sur-
face in the area within 4 A˚ from the ligand was larger in
models for PI3Ka than that in models for mTOR. Similar
binding modes of PKI-587 to PI3Ka and mTOR were
observed, which may be one of the key factors to the
success of its dual inhibition bioactivity against both
receptors.
Conclusion
To understand the molecular basis of a dual inhibitor of
PI3K/mTOR that contains the morpholino-triazine moiety,
we constructed pharmacophore and QSAR models using
experimentally identified PI3K and mTOR inhibitors with
the scaffold of morpholino-triazine. We also studied the
binding modes of MACs, LACs, and PKI-587, by docking
them to PI3Ka and mTOR. The pharmacophore models
were the same for PI3Ka and mTOR. It appeared that
MACs for PI3Ka and mTOR shared the same mechanism
of the inhibition as suggested by the QSAR model and
docking study. Binding modes from the docking study
revealed that both MACs and LACs mostly adopted a flat
plane conformation except the parts at the end of the
molecules. Based on the docked structures to both PI3Ka
and mTOR, the binding modes of MAC and LAC differed
by one HB formed with amine on the one end of the ligand
molecule. Similar binding modes were observed for PKI-
587 docked to PI3Ka and mTOR, which might be a key
principle for achieving dual inhibition bioactivity. The
analysis also suggested the importance of the space
surrounding the ligand in the binding pocket and of the
slight difference of the shape of the binding site between
PI3Ka and mTOR for the design of selective inhibitors.
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